Luisa M Villar Selected Research

Therapeutics

1/2023	Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis.
1/2020	Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis.
1/2020	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.
8/2014	Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.
10/2013	Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).
4/2013	[Biomarkers in multiple sclerosis].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Luisa M Villar Research Topics

Disease

40	Multiple Sclerosis 04/2024 - 02/2003
5	Chronic Progressive Multiple Sclerosis 11/2023 - 08/2014
3	Disease Progression 11/2023 - 08/2014
3	Progressive Multifocal Leukoencephalopathy 03/2019 - 10/2005
2	Nervous System Diseases (Neurological Disorders) 01/2023 - 06/2017
2	Inflammation (Inflammations) 01/2022 - 08/2014
2	Ganglion Cysts (Ganglion) 10/2021 - 01/2016
2	Rheumatoid Arthritis 01/2021 - 01/2020
2	Neuroinflammatory Diseases 01/2020 - 10/2014
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2020 - 10/2018
2	Demyelinating Diseases (Demyelinating Disease) 01/2012 - 01/2005
1	Infections 01/2024
1	COVID-19 01/2024
1	Optic Neuritis (Retrobulbar Neuritis) 10/2021
1	Lymphopenia (Lymphocytopenia) 03/2019
1	Opportunistic Infections (Opportunistic Infection) 03/2015
1	Monoclonal Gammopathy of Undetermined Significance 03/2014
1	Multiple Myeloma 03/2014
1	Atrophy 01/2012
1	Central Nervous System Infections (Central Nervous System Infection) 04/2005
1	Motor Neuron Disease (Primary Lateral Sclerosis) 04/2005

Drug/Important Bio-Agent (IBA)

15	Oligoclonal BandsIBA 01/2023 - 01/2005
14	Biomarkers (Surrogate Marker)IBA 04/2024 - 04/2013
6	Immunoglobulin M (IgM)IBA 10/2021 - 02/2003
6	LipidsIBA 10/2021 - 10/2010
5	Proteins (Proteins, Gene)FDA Link 04/2024 - 01/2020
5	Immunoglobulin G (IgG)IBA 01/2024 - 04/2005
4	ChitinasesIBA 11/2021 - 04/2015
4	AntibodiesIBA 01/2021 - 06/2012
4	Natalizumab (Tysabri)FDA Link 01/2020 - 10/2005
4	AntigensIBA 09/2014 - 11/2012
3	teriflunomideIBA 01/2024 - 01/2019
3	Interferon-betaIBA 10/2018 - 01/2017
2	Dimethyl FumarateIBA 01/2023 - 03/2019
2	Retinaldehyde (Retinal)IBA 10/2021 - 01/2016
2	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 01/2020
2	EnzymesIBA 01/2019 - 10/2014
2	AutoantibodiesIBA 01/2016 - 09/2014
1	CytokinesIBA 04/2024
1	ChemokinesIBA 04/2024
1	Immunologic Factors (Immunomodulators)IBA 01/2024
1	Neutralizing AntibodiesIBA 01/2024
1	ClusterinIBA 01/2024
1	Fingolimod Hydrochloride (FTY720)FDA Link 01/2023
1	MicroRNAs (MicroRNA)IBA 01/2023
1	Cladribine FDA LinkGeneric 01/2023
1	ocrelizumabIBA 01/2022
1	Methotrexate (Mexate)FDA LinkGeneric 01/2021
1	syncytinIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Leucine (L-Leucine)FDA Link 01/2020
1	LipopolysaccharidesIBA 01/2020
1	Adenosine Triphosphate (ATP)IBA 01/2020
1	Acetates (Acetic Acid Esters)FDA Link 01/2020
1	PyrinIBA 01/2020
1	Interleukin-1beta (Interleukin 1 beta)IBA 01/2020
1	InflammasomesIBA 01/2020
1	pyrimidineIBA 01/2019
1	Dihydroorotate DehydrogenaseIBA 01/2019
1	Histone MethyltransferasesIBA 10/2018
1	Polycomb Repressive Complex 2IBA 10/2018
1	PlasminogenIBA 01/2016
1	Cytidine DeaminaseIBA 10/2014
1	Immunoglobulins (Immunoglobulin)IBA 03/2014
1	AutoantigensIBA 08/2013

Therapy/Procedure

6	Therapeutics 01/2023 - 04/2013
1	Home Nursing (Nursing, Home) 01/2024
1	Biological Therapy 01/2021
1	Precision Medicine 01/2020
1	Cell- and Tissue-Based Therapy (Cell Therapy) 10/2013